Osteoarthritis year in review 2021: epidemiology &amp; therapy

Quicke, J.G.; Conaghan, Philip G.; Corp, Nadia; Peat, George

doi:10.1016/j.joca.2021.10.003

Cited by 212 publications

(149 citation statements)

References 61 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Osteoarthritis (OA) is the most common chronic disease of large joints, such as the knee, hip and hand joints, that mostly occurs in elderly individuals, with an incidence of greater than 60% in individuals over 65 years of age and that may further rise within the next 30 years [1,2]. OA does not only shatter joint functions and physical abilities but also brings long-term, considerable pain in patients [8].…”

Section: Osteoarthritismentioning

confidence: 99%

See 1 more Smart Citation

Mitochondrial Genome Editing to Treat Human Osteoarthritis—A Narrative Review

Zhong

Madry

Cucchiarini

2022

IJMS

View full text Add to dashboard Cite

Osteoarthritis (OA) is a severe, common chronic orthopaedic disorder characterised by a degradation of the articular cartilage with an incidence that increases over years. Despite the availability of various clinical options, none can stop the irreversible progression of the disease to definitely cure OA. Various mutations have been evidenced in the mitochondrial DNA (mtDNA) of cartilage cells (chondrocytes) in OA, leading to a dysfunction of the mitochondrial oxidative phosphorylation processes that significantly contributes to OA cartilage degeneration. The mitochondrial genome, therefore, represents a central, attractive target for therapy in OA, especially using genome editing procedures. In this narrative review article, we present and discuss the current advances and breakthroughs in mitochondrial genome editing as a potential, novel treatment to overcome mtDNA-related disorders such as OA. While still in its infancy and despite a number of challenges that need to be addressed (barriers to effective and site-specific mtDNA editing and repair), such a strategy has strong value to treat human OA in the future, especially using the groundbreaking clustered regularly interspaced short palindromic repeats (CRIPSR)/CRISPR-associated 9 (CRISPR/Cas9) technology and mitochondrial transplantation approaches.

show abstract

Section: Osteoarthritismentioning

confidence: 99%

“…Osteoarthritis (OA) is the most prevalent chronic joint disorder that affects millions of adult individuals worldwide [1,2]. The progressive, irreversible degradation of the extracellular cartilage matrix (ECM) with the persistence of chronic inflammation are all hallmarks of OA [3][4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Mitochondrial Genome Editing to Treat Human Osteoarthritis—A Narrative Review

Zhong

Madry

Cucchiarini

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Osteoarthritis (OA) is a common category of arthritis, which significantly impairs the functional status and quality of life in people all over the world [1,2]. Accumulating evidence from epidemiological studies suggested that diabetes may confer a higher risk of OA [3,4], although the results were not always consistent [5].…”

Section: Introductionmentioning

confidence: 99%

Association Between Prediabetes and Osteoarthritis: A Meta-Analysis

Zhou

Liu

2022

Horm Metab Res

View full text Add to dashboard Cite

Some studies have suggested that diabetes may be a risk factor for osteoarthritis. However, whether prediabetes is also associated with osteoarthritis has not been comprehensively examined. We performed a meta-analysis to evaluate the relationship between prediabetes and osteoarthritis. This meta-analysis included relevant observational studies from Medline, Embase, and Web of Science databases. A random-effect model after incorporation of the intra-study heterogeneity was selected to pool the results. Ten datasets from six observational studies were included, which involved 41 226 general adults and 10 785 (26.2%) of them were prediabetic. Pooled results showed that prediabetes was not independently associated with osteoarthritis [risk ratio (RR): 1.07, 95% confidence interval (CI): 1.00 to 1.14, p=0.06, I2=0%]. Sensitivity limited to studies with adjustment of age and body mass index showed consistent result (RR: 1.06, 95% CI: 0.99 to 1.14, p=0.09, I2=0%). Results of subgroup analyses showed that prediabetes was not associated with osteoarthritis in cross-sectional or cohort studies, in studies including Asian or non-Asian population, or in studies with different quality scores (p for subgroup difference>0.10). Besides, prediabetes was not associated with osteoarthritis in men or in women, in studies with prediabetes defined as impaired fasting glucose, impaired glucose tolerance, or HbA1c (approximately 39–46 mmol/mol). Moreover, prediabetes was not associated with overall osteoarthritis, and knee or hip osteoarthritis. Current evidence does not support that prediabetes is independently associated with osteoarthritis in adult population.

show abstract

“…The percent increases in primary THA and primary TKA compared to the 2014 numbers were 284% and 401%, respectively [ 1 ]. However, periprosthetic osteolysis (PPO) and aseptic loosening are the most common complications of TJR surgeries and are almost unavoidable issues that lead to a reduced quality of life and increased risk of instability in these patients [ 2 , 3 ]. In addition, the mechanism of PPO has not been fully elucidated, which increases the difficulty in the treatment of PPO.…”

Section: Introductionmentioning

confidence: 99%

NOX4 blockade suppresses titanium nanoparticle-induced bone destruction via activation of the Nrf2 signaling pathway

et al. 2022

View full text Add to dashboard Cite

Periprosthetic osteolysis (PPO) triggered by wear particles is the most severe complication of total joint replacement (TJR) surgeries, representing the major cause of implant failure, which is public health concern worldwide. Previous studies have confirmed the specialized role of osteoclast-induced progressive bone destruction in the progression of PPO. Additionally, the reactive oxygen species (ROS) induced by wear particles can promote excessive osteoclastogenesis and bone resorption. Nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4), a cellular enzyme, is considered to be responsible for the production of ROS and the formation of mature osteoclasts. However, NOX4 involvement in PPO has not yet been elucidated. Therefore, we investigated the mechanism by which NOX4 regulates osteoclast differentiation and the therapeutic effects on titanium nanoparticle-induced bone destruction. We found that NOX4 blockade suppressed osteoclastogenesis and enhanced the scavenging of intracellular ROS. Our rescue experiment revealed that nuclear factor-erythroid 2-related factor 2 (Nrf2) silencing reversed the effects of NOX4 blockade on ROS production and osteoclast differentiation. In addition, we found increased expression levels of NOX4 in PPO tissues, while NOX4 inhibition in vivo exerted protective effects on titanium nanoparticle-induced osteolysis through antiosteoclastic and antioxidant effects. Collectively, these findings suggested that NOX4 blockade suppresses titanium nanoparticle-induced bone destruction via activation of the Nrf2 signaling pathway and that NOX4 blockade may be an attractive therapeutic approach for preventing PPO. Graphical Abstract

show abstract

Osteoarthritis year in review 2021: epidemiology & therapy

Cited by 212 publications

References 61 publications

Mitochondrial Genome Editing to Treat Human Osteoarthritis—A Narrative Review

Mitochondrial Genome Editing to Treat Human Osteoarthritis—A Narrative Review

Association Between Prediabetes and Osteoarthritis: A Meta-Analysis

NOX4 blockade suppresses titanium nanoparticle-induced bone destruction via activation of the Nrf2 signaling pathway

Contact Info

Product

Resources

About